Jeff Albers, Blueprint CEO

July 14, 2020 06:01 AM EDTUpdated 07:09 AM

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

CRISPR patent spat revived by federal appeals court ruling

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

UnitedHealth Group CEO Andrew Witty steps down

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

HHS focuses on 'transparency' in third-round IRA negotiation guidance